Index RUT
P/E -
EPS (ttm) -2.75
Insider Own 13.77%
Shs Outstand 70.77M
Perf Week -8.92%
Market Cap 210.49M
Forward P/E -
EPS next Y -3.56
Insider Trans -0.13%
Shs Float 61.32M
Perf Month -9.76%
Income -194.65M
PEG -
EPS next Q -0.89
Inst Own 100.05%
Short Float 18.87%
Perf Quarter -73.29%
Sales 40.56M
P/S 5.19
EPS this Y 35.18%
Inst Trans -1.04%
Short Ratio 7.78
Perf Half Y -80.07%
Book/sh 5.38
P/B 0.55
EPS next Y -22.88%
ROA -34.97%
Short Interest 11.57M
Perf Year -88.30%
Cash/sh 6.00
P/C 0.49
EPS next 5Y -
ROE -42.98%
52W Range 2.83 - 25.81
Perf YTD -80.46%
Dividend Est. -
P/FCF -
EPS past 5Y -50.05%
ROI -45.92%
52W High -88.53%
Beta 1.69
Dividend TTM -
Quick Ratio 6.59
Sales past 5Y -20.00%
Gross Margin 96.71%
52W Low 4.59%
ATR (14) 0.32
Dividend Ex-Date -
Current Ratio 6.59
EPS Y/Y TTM 42.78%
Oper. Margin -543.77%
RSI (14) 38.36
Volatility 9.58% 9.69%
Employees 168
Debt/Eq 0.12
Sales Y/Y TTM -
Profit Margin -479.92%
Recom 2.27
Target Price 9.90
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 32.87%
Payout -
Rel Volume 0.50
Prev Close 3.24
Sales Surprise -
EPS Surprise -47.48%
Sales Q/Q -
Earnings Aug 09 BMO
Avg Volume 1.49M
Price 2.96
SMA20 -6.60%
SMA50 -18.98%
SMA200 -71.58%
Trades
Volume 748,156
Change -8.64%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-12-24 Upgrade
Wedbush
Underperform → Neutral
$4
Jun-20-24 Downgrade
UBS
Buy → Neutral
$28 → $5
Jun-18-24 Downgrade
Wells Fargo
Overweight → Equal Weight
Jun-18-24 Downgrade
Wedbush
Neutral → Underperform
$15 → $4
Jun-18-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$38 → $8
Jun-18-24 Downgrade
Jefferies
Buy → Hold
$42 → $6
Nov-08-23 Downgrade
Wedbush
Outperform → Neutral
$38 → $12
Nov-07-23 Downgrade
Leerink Partners
Outperform → Market Perform
$15
Jul-12-22 Initiated
Cowen
Outperform
Apr-06-22 Initiated
Wells Fargo
Overweight
$67
Oct-07-21 Resumed
Jefferies
Buy
$120
Sep-30-21 Initiated
Stifel
Buy
$84
Sep-29-21 Initiated
Oppenheimer
Outperform
$90
May-21-21 Initiated
UBS
Buy
$91
Jan-20-21 Initiated
Wedbush
Outperform
$65
Sep-29-20 Initiated
Cantor Fitzgerald
Overweight
$44
Aug-27-20 Initiated
H.C. Wainwright
Buy
$43
Apr-28-20 Initiated
SVB Leerink
Outperform
$45
Apr-28-20 Initiated
Morgan Stanley
Overweight
$45
Apr-28-20 Initiated
Jefferies
Buy
$41
Show Previous Ratings
Sep-03-24 04:40PM
Aug-26-24 11:58AM
Aug-09-24 02:53PM
07:00AM
Aug-01-24 06:00PM
06:00PM
Loading…
Jul-01-24 06:00PM
Jun-19-24 10:23AM
04:52AM
Jun-18-24 07:00AM
Jun-03-24 06:00PM
Jun-01-24 02:43AM
May-30-24 07:00AM
May-29-24 07:00AM
May-23-24 05:01PM
May-14-24 07:00AM
10:27AM
Loading…
May-08-24 10:27AM
May-07-24 09:04PM
01:54PM
07:00AM
May-01-24 05:30PM
Apr-02-24 04:05PM
(GlobeNewswire) -10.54%
+8.25%
Apr-01-24 05:30PM
Mar-01-24 06:00PM
Feb-28-24 09:55AM
07:00AM
Feb-27-24 07:01PM
07:00AM
Feb-14-24 09:35AM
Feb-13-24 07:00AM
Feb-08-24 12:00PM
11:26PM
Loading…
Feb-05-24 11:26PM
Feb-01-24 05:00PM
Jan-25-24 07:00AM
Jan-08-24 07:00AM
Jan-02-24 04:49PM
Dec-01-23 05:39PM
Nov-13-23 09:03PM
Nov-09-23 07:00AM
Nov-06-23 07:13PM
(GuruFocus.com) -30.20%
-18.27%
07:18AM
Nov-01-23 04:52PM
Oct-07-23 05:00AM
Oct-02-23 04:27PM
Sep-14-23 01:02AM
Sep-06-23 07:00AM
Sep-01-23 04:37PM
Aug-09-23 07:00AM
Aug-01-23 04:28PM
07:00AM
Jun-15-23 06:01AM
Jun-06-23 06:00AM
Jun-02-23 02:34PM
May-26-23 12:33PM
10:53AM
May-25-23 05:38PM
May-23-23 07:00AM
May-12-23 09:55AM
May-10-23 07:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Mar-01-23 07:00AM
Feb-13-23 07:00AM
Feb-01-23 05:00PM
07:01AM
Jan-17-23 09:18AM
Jan-03-23 05:00PM
Dec-08-22 09:55AM
Dec-01-22 05:00PM
Nov-09-22 07:00AM
Nov-08-22 07:01AM
Nov-01-22 05:38PM
Oct-24-22 07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:32PM
Sep-27-22 04:01PM
Sep-19-22 07:00AM
Sep-12-22 07:00AM
Sep-01-22 05:00PM
Aug-31-22 07:00AM
Aug-26-22 12:00PM
Aug-16-22 09:55AM
Aug-10-22 04:39PM
10:01AM
08:40AM
Aug-09-22 04:01PM
Aug-03-22 07:00AM
Aug-01-22 05:10PM
Jun-27-22 07:00AM
Jun-14-22 09:10AM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-26-22 09:48AM
May-21-22 09:48AM
May-18-22 04:01PM
May-16-22 07:28AM
07:00AM
May-05-22 07:00AM
Apr-27-22 10:17AM
07:00AM
Apr-19-22 09:35AM
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gallagher Cam President, Interim CFO May 31 '24 Sale 11.98 9,597 114,972 633,680 May 31 06:27 PM HAUSMAN DIANA Chief Medical Officer May 09 '24 Sale 12.62 3,356 42,353 373,876 May 09 07:46 PM Epperly Melissa B, Chief Financial Officer Feb 12 '24 Sale 11.44 2,573 29,435 451,449 Feb 12 08:22 PM Gallagher Cam President Feb 12 '24 Sale 11.44 1,173 13,419 643,277 Feb 12 08:21 PM Lackner Mark Chief Scientific Officer Feb 02 '24 Sale 11.54 1,585 18,291 195,728 Feb 05 07:15 PM Paul Andrea Chief Legal Officer Feb 02 '24 Sale 11.54 3,310 38,197 149,973 Feb 05 07:14 PM Gallagher Cam President Feb 02 '24 Sale 11.54 11,552 133,310 644,450 Feb 05 07:13 PM Epperly Melissa B, Chief Financial Officer Feb 02 '24 Sale 11.54 8,669 100,040 454,022 Feb 05 07:12 PM Johnson David Michael Director Nov 10 '23 Buy 9.88 17,000 167,943 144,389 Nov 13 05:24 PM Blackwell Kimberly Chief Executive Officer Nov 13 '23 Buy 10.29 5,000 51,448 254,800 Nov 13 05:24 PM Brownstein Carrie Chief Medical Officer Oct 04 '23 Sale 19.50 10,628 207,298 105,685 Oct 06 07:19 PM Bunker Kevin D. Chief Scientific Officer Oct 04 '23 Sale 19.50 6,068 118,355 859,089 Oct 06 07:19 PM Epperly Melissa B, Chief Financial Officer Oct 04 '23 Sale 19.50 5,482 106,926 387,691 Oct 06 07:18 PM Skvarka Jan Director Sep 11 '23 Sale 25.05 5,000 125,238 47,970 Sep 13 04:11 PM
Index RUT
P/E -
EPS (ttm) -1.79
Insider Own 15.81%
Shs Outstand 49.35M
Perf Week -0.89%
Market Cap 385.97M
Forward P/E -
EPS next Y -1.95
Insider Trans 0.00%
Shs Float 41.76M
Perf Month -5.01%
Income -80.69M
PEG -
EPS next Q -0.44
Inst Own 72.83%
Short Float 2.94%
Perf Quarter 4.15%
Sales 0.00M
P/S -
EPS this Y 10.10%
Inst Trans 2.21%
Short Ratio 6.93
Perf Half Y -10.98%
Book/sh 3.86
P/B 2.01
EPS next Y -12.49%
ROA -39.26%
Short Interest 1.23M
Perf Year -25.26%
Cash/sh 3.78
P/C 2.06
EPS next 5Y -
ROE -45.09%
52W Range 5.99 - 12.35
Perf YTD -12.19%
Dividend Est. -
P/FCF -
EPS past 5Y -16.85%
ROI -38.84%
52W High -37.00%
Beta 0.35
Dividend TTM -
Quick Ratio 18.54
Sales past 5Y 0.00%
Gross Margin -
52W Low 29.88%
ATR (14) 0.51
Dividend Ex-Date -
Current Ratio 18.54
EPS Y/Y TTM 10.80%
Oper. Margin 0.00%
RSI (14) 46.61
Volatility 6.16% 6.10%
Employees 89
Debt/Eq 0.10
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 20.00
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 15.10%
Payout -
Rel Volume 0.54
Prev Close 7.82
Sales Surprise -
EPS Surprise 8.91%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 177.20K
Price 7.78
SMA20 -0.91%
SMA50 -6.23%
SMA200 -3.08%
Trades
Volume 95,149
Change -0.51%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-25-24 Initiated
H.C. Wainwright
Buy
$21
Jul-27-23 Initiated
Scotiabank
Sector Outperform
Apr-17-23 Resumed
BTIG Research
Buy
$38
Jul-19-22 Initiated
JMP Securities
Mkt Outperform
$26
Sep-03-24 04:05PM
Aug-28-24 04:05PM
Aug-26-24 04:05PM
Aug-08-24 07:00AM
Jun-06-24 09:55AM
04:05PM
Loading…
May-30-24 04:05PM
May-23-24 08:00AM
May-10-24 02:58PM
May-09-24 01:55PM
07:00AM
May-08-24 07:00AM
Mar-27-24 01:53PM
07:00AM
Mar-17-24 05:20PM
Feb-26-24 07:00AM
09:55AM
Loading…
Dec-11-23 09:55AM
Dec-07-23 08:00AM
Nov-23-23 09:55AM
Nov-09-23 04:05PM
Nov-08-23 07:00AM
Nov-06-23 10:02PM
(Business Wire) -8.18%
-32.55%
04:08PM
03:00PM
Oct-31-23 04:05PM
(Business Wire) +9.24%
+9.93%
Oct-02-23 04:05PM
Aug-09-23 07:00AM
Jul-31-23 06:07AM
May-24-23 04:05PM
May-12-23 07:00AM
May-11-23 04:10PM
07:52AM
Loading…
May-03-23 07:52AM
Mar-15-23 04:10PM
11:11AM
Feb-16-23 10:43AM
07:00AM
Feb-10-23 06:03AM
Feb-09-23 07:00AM
Dec-24-22 09:27AM
Dec-16-22 09:54AM
Nov-30-22 08:50PM
04:01PM
Nov-24-22 06:34AM
Nov-10-22 07:00AM
06:45AM
Nov-03-22 07:00AM
Oct-06-22 10:12AM
Oct-04-22 07:05AM
Oct-03-22 01:37PM
07:00AM
Sep-28-22 07:00AM
Sep-27-22 07:00AM
Sep-07-22 07:00AM
Sep-01-22 07:00AM
Aug-11-22 04:15PM
(Business Wire) -8.60%
+8.89%
Aug-02-22 07:00AM
Jul-19-22 03:04PM
Jul-17-22 08:36AM
Jun-30-22 08:51AM
07:00AM
Jun-23-22 08:44AM
Jun-22-22 04:30PM
Jun-17-22 07:00AM
06:40AM
May-26-22 05:26PM
May-25-22 07:00AM
May-12-22 04:15PM
May-03-22 04:05PM
07:00AM
Apr-29-22 07:53AM
Mar-23-22 04:15PM
Mar-21-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 04:30PM
Feb-28-22 07:00AM
Feb-14-22 05:00PM
Feb-09-22 08:00AM
Feb-03-22 01:38PM
Jan-29-22 07:52AM
Nov-24-21 04:05PM
(Business Wire) +11.36%
+13.16%
Nov-23-21 04:05PM
Nov-15-21 11:00AM
Oct-28-21 09:39PM
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
de los Pinos Elisabet See Remarks Jan 23 '24 Sale 7.64 15,853 121,141 161,438 Jan 24 04:20 PM Feder Julie B Chief Financial Officer Jan 23 '24 Sale 7.64 6,609 50,521 62,991 Jan 24 04:18 PM Johnson David Michael Director Nov 07 '23 Buy 7.17 94,000 673,980 65,000 Nov 09 05:02 PM Johnson David Michael Director Nov 07 '23 Buy 7.17 76,000 544,920 126,066 Nov 09 05:02 PM Johnson David Michael Director Nov 08 '23 Buy 7.30 20,000 146,000 75,000 Nov 09 05:02 PM Johnson David Michael Director Nov 08 '23 Buy 7.30 9,601 70,087 135,667 Nov 09 05:02 PM Matrix Capital Management Comp 10% Owner Nov 09 '23 Buy 9.00 1,560,000 14,040,000 6,922,870 Nov 09 04:35 PM de los Pinos Elisabet See Remarks Nov 06 '23 Option Exercise 2.74 3,800 10,412 184,740 Nov 07 06:19 PM de los Pinos Elisabet See Remarks Nov 06 '23 Sale 12.03 7,449 89,611 177,291 Nov 07 06:19 PM Feder Julie B Chief Financial Officer Nov 06 '23 Option Exercise 2.74 3,900 10,686 73,500 Nov 07 06:09 PM Feder Julie B Chief Financial Officer Nov 06 '23 Sale 12.07 3,900 47,054 69,600 Nov 07 06:09 PM Feder Julie B Chief Financial Officer Oct 30 '23 Sale 6.82 3,385 23,091 69,600 Nov 01 06:24 PM de los Pinos Elisabet See Remarks Oct 30 '23 Sale 6.83 9,586 65,478 180,940 Nov 01 06:21 PM Johnson David Michael Director Oct 03 '23 Buy 8.27 13,500 111,663 43,500 Oct 05 07:56 PM Johnson David Michael Director Oct 04 '23 Buy 8.61 6,566 56,512 50,066 Oct 05 07:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite